Nanocarrier Delivery Systems for Epilepsy: A Preclinical Landscape Review

This narrative review catalogs lipid, vesicular, polymeric, and inorganic nanocarrier strategies designed to overcome blood-brain barrier and drug-resistance barriers in epilepsy, but all supporting efficacy data are preclinical.

nanocarriersnanoparticlesliposomessolid lipid nanoparticlesnanostructured lipid carriersepilepsydrug-resistant epilepsyblood-brain barrierdrug deliverycarbamazepinelamotriginenarrative reviewneuropharmacology Neurology / Neuropharmacology

Background Information

Nanocarriers show potential for improving epilepsy drug delivery.

Epilepsy treatments face challenges like poor blood-brain barrier (BBB) penetration and drug resistance, limiting their effectiveness. Nanocarriers improve the brain targeting and effectiveness of antiepileptic drugs by enhancing BBB penetration and drug stability in preclinical studies. While nanocarriers offer promising improvements in epilepsy treatment, issues such as large-scale manufacturing and regulatory approval need resolution before clinical application. Nanocarrier technology shows promise for enhancing antiepileptic drug delivery.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Chauhan A, Kumar A, Awasthi A, Bhatia R

Citation: Chauhan A, Kumar A, Awasthi A, et al. Nanocarrier-based targeting strategies in epilepsy: addressing pathophysiological barriers. The Journal of pharmacy and pharmacology. 2026;78(7). doi:10.1093/jpp/rgag077

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →